Mission Statement

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of mitochondrial dysfunction, the company is advancing its lead drug candidate sonlicromanol for the treatment of patients suffering from several primary mitochondrial diseases first. Currently being tested in Phase II studies in both children and adults, sonlicromanol is one of the most advanced disease-modifying mitochondrial medicines under development.

On the web